A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

• ClinicalTrials.gov Identifier: NCT03574389
• Recruitment Status: Active, not recruiting
• First Posted: July 2, 2018
• Last Update Posted: December 20, 2021
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.

Condition or disease	Intervention/treatment	Phase
Pneumococcal Infections; Pneumococcal Conjugate Vaccine	Biological: 13vPnC; Biological: Hib	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 936 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION
• Actual Study Start Date: June 23, 2018
• Actual Primary Completion Date: August 23, 2021
• Estimated Study Completion Date: December 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: 13-valent Pneumococcal Conjugate Vaccine (13vPnC); Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.; Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).; Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.; Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age.	Biological: 13vPnC; suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Active Comparator: Haemophilus influenzae type b (Hib); No participants in cohort 1 will receive Hib vaccine.; Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.; Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age.	Biological: Hib; suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Outcome Measures

Primary Outcome Measures :

1. Serotype-specific IgG geometric mean concentrations(GMCs) for each of the pneumococcal serotypes compared to IgG GMCs [ Time Frame: 1 month after the last dose of 13vPnC in cohorts 2, 3 and 4 and 1 month after the infant series in cohort 1 ]
   The serotype-specific IgG geometric mean concentrations (GMCs) for each of the pneumococcal serotypes measured 1 month after the last dose of 13vPnC in Cohort 2, 3, 4 compared to IgG GMCs measured 1 month after the infant series in Cohort 1.
2. Number of local reactions and systemic events in Cohorts 2, 3 and 4 [ Time Frame: 7 days after each vaccination ]
   The incidence of local reactions and systemic events (including the use of antipyretic medication) in the 7 days after each vaccination (13vPnC or Hib) in Cohorts 2, 3 and 4.
3. Number of Adverse Events (AE) from the signing of the informed consent document (ICD) to 1 month after the last vaccination (13vPnC or Hib) in Cohort 2, 3 and 4 [ Time Frame: 1 month after the last vaccination (13vPnC or Hib) in Cohort 2, 3 and 4 ]
4. Number of newly diagnosed chronic medical conditions in Cohort 2, 3 and 4 [ Time Frame: 1 month after the last study vaccination to 6 months after the last study vaccination ]
   The incidence of newly diagnosed chronic medical conditions from 1 month after the last study vaccination (13vPnC or Hib) to 6 months after the last study vaccination in Cohort 2, 3 and 4.
5. Number of serious adverse events (SAEs) from the signing of the informed consent document (ICD) to 6 months after the last study vaccination (13vPnC or Hib) in Cohort 2, 3 and 4 [ Time Frame: Up to 6 months after the last study vaccination (13vPnC or Hib) in Cohort 2, 3 and 4 ]

Secondary Outcome Measures :

1. Opsonophagocytic activity (OPA) to the vaccine specific serotypes compared to vaccine specific responses OPA [ Time Frame: 1 month after the last dose of 13vPnC in cohorts 2,3, 4 and 1 month after infant series in cohort 1 ]
   The serotype-specific OPA geometric mean titers (GMTs) for each of the pneumococcal serotypes measured in a subset of approximately 50 subjects per cohort measured 1 month after the last dose of 13vPnC in Cohort 2, 3, 4 compared to OPA GMTs measured 1 month after the infant series in Cohort 1.
2. Serotype specific IgG GMC and OPA GMTs for each of the pneumococcal serotypes compared to IgG and OPA [ Time Frame: 1 month after the last vaccination in Cohort 2, 3, 4, whichever comes last, up to 9 months ]

   Serotype specific IgG GMC in all subjects and OPA GMTs in approximately 50 subjects per cohort vaccinated with 13vPnC (Cohorts 1,2 ,3 4) and approximately 25 subjects per cohorts vaccinated with Hib (Cohort 2, 3, 4) using blood drawn at the following visits:

   • Cohort 2: Visit 1, Visit 4
   • Cohort 3: Visit 1, Visit 3
   • Cohort 4: Visit 1, Visit 2
3. Serotype specific IgG GMC for each of the pneumococcal serotypes [ Time Frame: Before vaccination through 5 years of age ]
   Serotype specific IgG GMC in all subjects and OPA GMTs in approximately 50 subjects at all times points in Cohort 1.
4. Number of AEs from the signing of the informed consent document (ICD) to 1 month after vaccination 3 in Cohort 1 [ Time Frame: Up to 1 month after vaccination 3 in Cohort 1 ]
5. Number of newly diagnosed chronic medical conditions from 1 month after vaccination 3 to vaccination 4 in Cohort 1 [ Time Frame: 1 month after vaccination 3 to vaccination 4 in Cohort 1 ]
6. Number of AEs from vaccination 4 to 1 month after vaccination 4 in Cohort 1 [ Time Frame: Vaccination 4 to 1 month after vaccination 4 in Cohort 1 ]
7. Number of newly diagnosed chronic medical conditions from 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1 [ Time Frame: 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1 ]
8. Number of serious adverse events (SAEs) from the signing of the informed consent document (ICD) to 6 months after vaccination 4 in Cohort 1 [ Time Frame: Up to 6 months after vaccination 4 in Cohort 1 ]

Eligibility Criteria

• Ages Eligible for Study: 42 Days to 5 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Evidence of a personally signed and dated ICD indicating that the parent(s)/legal guardian has been informed of all pertinent aspects of the study.
• Aged 6 weeks (42 days) to <6 years at the time of consent.
• Healthy infants and children as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

• Participation in other studies involving investigational drug(s)/vaccine(s) since birth (Cohort 1 only) or in the 6 months prior to study entry (Cohorts 2, 3, and 4) and/or during study participation.
• Other acute or chronic medical or psychiatric condition, including recent laboratory abnormality, that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
• Vaccination with licensed or investigational pneumococcal vaccine.
• Previous vaccination with licensed or investigational Hib vaccine.

Contacts and Locations

Locations

China, Jiangsu

Huaiyin District Center for Disease Prevention and Control

Huaian, Jiangsu, China, 223300

Guanyun County Disease Control and Prevention

Lianyungang, Jiangsu, China

Sponsors and Collaborators

Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. 

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT03574389
• Other Study ID Numbers: B1851178
• First Posted: July 2, 2018
• Last Update Posted: December 20, 2021
• Last Verified: December 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
• URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pneumococcal Infections; Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections